M
Manuel Pascual
Researcher at University of Lausanne
Publications - 229
Citations - 7789
Manuel Pascual is an academic researcher from University of Lausanne. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 50, co-authored 223 publications receiving 7183 citations. Previous affiliations of Manuel Pascual include University Hospital of Lausanne.
Papers
More filters
Journal ArticleDOI
Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries.
A. B. Collins,Eveline E. Schneeberger,Manuel Pascual,Susan L. Saidman,Winfred W. Williams,Nina Tolkoff-Rubin,Cosimi Ab,Robert B. Colvin +7 more
TL;DR: C4d in peritubular capillary walls distinguishes AHR from ACR, is more specific and sensitive than traditional criteria, and is a potentially valuable adjunct in the diagnosis of graft dysfunction.
Journal ArticleDOI
Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics.
Marta Crespo,Manuel Pascual,Nina Tolkoff-Rubin,Shamila Mauiyyedi,A. Bernard Collins,Donna M. Fitzpatrick,Mary Lin Farrell,Winfred W. Williams,Francis L. Delmonico,A. Benedict Cosimi,Robert B. Colvin,Susan L. Saidman +11 more
TL;DR: Most cases with DSA at the time of rejection had widespread C4d deposits in peritubular capillaries, suggesting a pathogenic role of the circulating alloantibody.
Journal ArticleDOI
Hepatitis C virus in patients with cryoglobulinemia type II.
Journal ArticleDOI
Cytomegalovirus in transplantation - challenging the status quo
Jay A. Fishman,Vincent C. Emery,Richard B. Freeman,Manuel Pascual,Lionel Rostaing,Hans J. Schlitt,Dino Sgarabotto,Julián Torre-Cisneros,Marc E. Uknis +8 more
TL;DR: Options for CMV prevention include pre‐emptive therapy, whereby anti‐CMV agents are administered based on sensitive viral assays, or universal prophylaxis of all at‐risk patients, which has advantages and disadvantages in terms of efficacy, costs, and side effects.
Journal ArticleDOI
Liver Transplantation for Neuroendocrine Tumors in Europe-Results and Trends in Patient Selection: A 213-Case European Liver Transplant Registry Study.
Yves Patrice Le Treut,Emilie Gregoire,Jürgen Klempnauer,Jacques Belghiti,Elisabeth Jouve,Jan Lerut,Denis Castaing,Olivier Soubrane,Olivier Boillot,Georges Mantion,Kia Homayounfar,Manuel Bustamante,Daniel Azoulay,Philippe Wolf,Marek Krawczyk,Andreas Pascher,Bertrand Suc,Laurence Chiche,Jorge Ortiz De Urbina,Vladimir Mejzlik,Manuel Pascual,J. Peter A. Lodge,Salvatore Gruttadauria,François Paye,François-René Pruvot,Stefan Thorban,Aksel Foss,René Adam +27 more
TL;DR: LT is an effective treatment of unresectable LM from neuroendocrine tumors (NET) over a 27-year period and patient selection based on the aforementioned predictors can achieve a 5-year OS between 60% and 80%.